NCT02769286View on ClinicalTrials.gov

Osimertinib in First and Second Line Treatment of NSCLC Harboring EGFR Mutations From Circulating Tumor DNA

PHASE2CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

August 31, 2016

Primary Completion Date

December 31, 2018

Study Completion Date

May 31, 2020

Conditions
Lung NeoplasmsEGFR Gene Mutations
Interventions
DRUG

Osimertinib

Treatment efficacy of osimertinib will be assessed in patients with lung cancer harboring EGFR mutations (cohort 1) and those harboring T790M (cohort 2) which were detected from circulating tumor DNA

Trial Locations (1)

58128

Chonnam National University Hwasun Hospital, Hwasun

All Listed Sponsors
lead

Chonnam National University Hospital

OTHER

NCT02769286 - Osimertinib in First and Second Line Treatment of NSCLC Harboring EGFR Mutations From Circulating Tumor DNA | Biotech Hunter | Biotech Hunter